RQ-00000010 for Gastroparesis and Constipation in Parkinson's Disease
Status:
Completed
Trial end date:
2019-08-20
Target enrollment:
Participant gender:
Summary
This is a study to determine the safety and tolerability of a new medicine (RQ10) for
gastrointestinal symptoms in Parkinson's disease. The investigators will also begin to look
at the effect of this medicine on gastrointestinal problems. The results will determine if
future studies are appropriate. In this study, RQ10 will be compared to a placebo (a
look-alike inactive substance). Participation will include multiple office visits.
Approximately 48 people will participate.
Phase:
Phase 1
Details
Lead Sponsor:
Leslie J. Cloud Virginia Commonwealth University
Collaborators:
Michael J. Fox Foundation for Parkinson's Research RaQualia Pharma Inc.